Skip to main content

Advertisement

Log in

A new scenario in metastatic renal cell carcinoma: a SOG-GU consensus

  • Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Background

This article describes and compares approved targeted therapies and the newer immunotherapy agents.

Materials and methods

This article especially performs an in-depth review of currently available data for tivozanib, explaining its mechanism of action, its safety profile and its role as an efficacy drug in the management of renal cancer.

Results

Despite the fact that the treatment of advanced RCC has been dramatically modified in recent years, durable remissions are scarce and it remains a lethal disease. For first- and second-line therapy, there is now growing evidence to guide the selection of the appropriate treatment.

Conclusions

Several TKIs are standard of care at different settings. Among those approved TKIs, tivozanib has similar efficacy than others with a better safety profile. The use of prognostic factors is critical to the selection of optimal therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492(Epub 2018 Sep 12).

    Article  Google Scholar 

  2. Ljungberg B, Campbell SC, Choi HY, et al. The epidemiology of renal cell carcinoma. Eur Urol. 2011;60(4):615–21.

    Article  Google Scholar 

  3. Rodriguez-Vida A, Hutson TE, Bellmunt J, et al. New treatment options for metastatic renal cell carcinoma. ESMO Open. 2017;2(2):e000185.

    Article  Google Scholar 

  4. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370:2103–11. https://doi.org/10.1016/S0140-6736(07)61904-7.

    Article  PubMed  Google Scholar 

  5. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–24. https://doi.org/10.1056/NEJMoa065044.

    Article  CAS  PubMed  Google Scholar 

  6. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28:1061–8. https://doi.org/10.1200/JCO.2009.23.9764.

    Article  CAS  PubMed  Google Scholar 

  7. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378:1931–9. https://doi.org/10.1016/S0140-6736(11)61613-9.

    Article  CAS  PubMed  Google Scholar 

  8. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271–81. https://doi.org/10.1056/NEJMoa066838 (PubMed).

    Article  CAS  PubMed  Google Scholar 

  9. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372:449–56. https://doi.org/10.1016/S0140-6736(08)61039-9.

    Article  CAS  PubMed  Google Scholar 

  10. Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014. https://doi.org/10.1093/annonc/mdz056.

    Article  PubMed  Google Scholar 

  11. Gill DM, Agarwal N, Vaishampayan U. Evolving treatment paradigm in metastatic renal cell carcinoma. Am Soc Clin Oncol Educ Book. 2017;37:319–29. https://doi.org/10.14694/EDBK_174469.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanims of anti-tumor activity. Nat Rev Cancer. 2008;8(8):579–91.

    Article  CAS  Google Scholar 

  13. Shibuya M. Vascular endothelial growth factor receptor-2: its unique signaling and specific ligand VEGF-E. Cancer Sci. 2003;94(9):751–6.

    Article  CAS  Google Scholar 

  14. Kowanetz M, Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res. 2006;12(7):5018–22.

    Article  CAS  Google Scholar 

  15. Eskens FALM, de Jonge MJA, Esteves B, et al. Updated results from a phase I study of AV-951 (KRN951), a potent selective VEGFR-1,-2, and -3 tyrosine kinases inhibitor, in patients with advanced solid tumors. ASCO, San Diego, CA Abstract LB-201; 2008.

  16. Bhargava P, Robinson MO. Development of second-generation VEGFR tyrosine kinase inhibitors: current status. Curr Oncol Rep. 2011;13(2):103–11.

    Article  CAS  Google Scholar 

  17. Escudier B, Goe M. Axitinib for the management of metastatic renal cell carcinoma. Drugs RD. 2011;11(2):113–26.

    Article  Google Scholar 

  18. Fotdiva, public assessment report, EMA; 2017.

  19. Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010;28(13):2137–43.

    Article  CAS  Google Scholar 

  20. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–24.

    Article  CAS  Google Scholar 

  21. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(22):3584–90.

    Article  CAS  Google Scholar 

  22. Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722–31.

    Article  CAS  Google Scholar 

  23. Motzer RJ, Nosov D, Eisen T, Bondarenko I, Lesovoy V, Lipatov O, et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol. 2013;31(30):3791–9.

    Article  CAS  Google Scholar 

  24. Molina AM, Hutson TE, Nosov D, Lipatov O, Sternberg C, et al. Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study. Eur J Cancer. 2018;94:87–94. https://doi.org/10.1016/j.ejca.2018.02.009.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Choueiri TK, Halabi S, Sanford BL, Hahn O, Michaelson MD, Walsh MK, et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial. J Clin Oncol. 2017;35(6):591–7.

    Article  CAS  Google Scholar 

  26. Choueiri TK, Hessel C, Halabi S, Sanford B, Michaelson MD, Hahn O, et al. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and overall survival update. Eur J Cancer. 2018;94:115–25.

    Article  CAS  Google Scholar 

  27. Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378:1277–90.

    Article  CAS  Google Scholar 

  28. Tannir NM, Frontera OA, Hammers HJ. 30-Month follow-up of the phase 3 CheckMate 214 trial of first-line nivolumab plus ipilimumab or sunitinib in patients with advanced renal cell carcinoma. ASCO-GU, editor. ASCO GU; 2019.

  29. McDermott D, Rini B, Motzer R. Treatment-free survival following discontinuation of first-line nivolumab plus ipilimumab or sunitinib in patients with advanced renal cell carcinoma: CheckMate 214 analysis. ESMO, editor. ESMO; 2018.

  30. Rini B, Plimack ER, Stus V, Gafanov R. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380:1–12.

    Article  Google Scholar 

  31. Motzer R, Powles T, Atkins M. IMmotion151: a randomized phase III study of atezolizumab plus bevacizumab versus sunitinib in untreated metastatic renal cell carcinoma. J Clin Oncol. 2018;36(Suppl 6S):Abstract578.

    Article  Google Scholar 

  32. Motzer R, Penkov K, Haanen J. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380:1–13.

    Article  Google Scholar 

  33. Barthelemy P, Escudier B, Ravaud A, Negrier S, Needle MN, et al. TiNivo—tivozanib combined with nivolumab: safety and efficacy in patients with metastatic renal cell carcinoma (mRCC). Ann Oncol. 2018;29(suppl_8):mdy283.087.

    Google Scholar 

  34. Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20:289–96.

    Article  CAS  Google Scholar 

  35. Motzer RJ, Escudier B, Bukowski R, Rini BI, Hutson TE, Barrios CH, et al. Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma. Br J Cancer. 2013;108:2470–7.

    Article  CAS  Google Scholar 

  36. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27:5794–9.

    Article  CAS  Google Scholar 

  37. Tamada S, Iguchi T, Yasuda S, Kato M, Yamasaki T, Nakatani T. The difference in the survival rate of patients with metastatic renal cell carcinoma in the intermediate-risk group of the Memorial Sloan Kettering Cancer Center criteria. Oncotarget. 2018;9:27752–9.

    Article  Google Scholar 

  38. Sella A, Michaelson MD, Matczak E, Simantov R, Lin X, Figlin RA. Heterogeneity of patients with intermediate-prognosis metastatic renal cell carcinoma treated with sunitinib. Clin Genitourin Cancer. 2017;15:291–9(e1).

    Article  Google Scholar 

  39. Iacovelli R, De Giorgi U, Galli L, Zucali P, Nole F, Sabbatini R, et al. Is it possible to improve prognostic classification in patients affected by metastatic renal cell carcinoma with an intermediate or poor prognosis? Clin Genitourin Cancer. 2018. https://doi.org/10.1016/j.clgc.2018.04.007(Epub ahead of print).

    Article  PubMed  Google Scholar 

  40. Rini BI, Hutson TE, Figlin RA, Lechuga MJ, Valota O, Serfass L, et al. Sunitinib in patients with metastatic renal cell carcinoma: clinical outcome according to international metastatic renal cell carcinoma database consortium risk group. Clin Genitourin Cancer. 2018;16:298–304.

    Article  Google Scholar 

  41. Procopio G, Bamias A, Schmidinger M, Hawkins R, Rodríguez Sánchez A, Vázquez Estévez S, et al. Real-world efectiveness of pazopanib in patients with intermediate prognostic risk advanced renal cell carcinoma (PRINCIPAL Study). Ann Oncol. 2018;29(suppl_8):vii303–viii331.

    Google Scholar 

  42. Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1814–23. https://doi.org/10.1056/NEJMoa1510016([PMC free article] [PubMed] [CrossRef]).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17:917–27. https://doi.org/10.1016/S1470-2045(16)30107-3.

    Article  CAS  PubMed  Google Scholar 

  44. Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16:1473–82. https://doi.org/10.1016/S1470-2045(15)00290-9.

    Article  CAS  PubMed  Google Scholar 

  45. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803–13. https://doi.org/10.1056/NEJMoa1510665([PMC free article] [PubMed] [CrossRef]).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/PDF/kidney.pdf. Accessed Jan 2017.

  47. Motzer RJ, Porta C, Vogelzang NJ, et al. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(3):286–96. https://doi.org/10.1016/S1470-2045(14)70030-0([PMC free article] [PubMed] [CrossRef]).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Calvo E, Escudier B, Motzer RJ, et al. Everolimus in metastatic renal cell carcinoma: subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. Eur J Cancer. 2012;48(3):333–9. https://doi.org/10.1016/j.ejca.2011.11.027.

    Article  CAS  PubMed  Google Scholar 

  49. Bedke J, Gauler T, Grünwald V, et al. Systemic therapy in metastatic renal cell carcinoma. World J Urol. 2017;35(2):179–88.

    Article  CAS  Google Scholar 

  50. Rini BI, Pal SK, Escudier B, Atkins MB, Hitson TE, et al. TIVO-3: a phase III, randomized, controlled, multicenter, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC). J Clin Oncol. 2019;37(7_suppl):541–541. https://doi.org/10.1200/JCO.2019.37.7_suppl.541.

    Article  Google Scholar 

  51. Porta C, Verzoni E, Escudier B, et al. TIVO-3: subgroup analysis of progression-free survival of tivozanib compared to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC). J Clin Oncol. 2019;37(15_suppl):4572–4572. https://doi.org/10.1200/JCO.2019.37.15_suppl.4572.

    Article  Google Scholar 

  52. Miyazaki A, Miyake H, Harada KI, Inoue TA, Fujisawa M. Prognostic outcome in patients treated with tyrosine kinase inhibitors as first-line molecular-targeted therapy for metastatic renal cell carcinoma: experience in real-world clinical practice in Japan. Mol Clin Oncol. 2015;3(3):601–6.

    Article  CAS  Google Scholar 

  53. Beuselinck B, Verbiest A, Couchy G, Job S, de Reynies S, et al. Tumor molecular characteristics in patients (pts) with international metastatic renal cell carcinoma database consortium (IMDC) good (G) and intermediate/poor (I/P) risk. Ann Oncol. 2018;29(suppl_8):mdy283.078.

    Google Scholar 

  54. Giraldo N, Becht E, Pages F, Skliris G, Verkarre V, et al. Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer. Clin Cancer Res. 2015;21(13):3031–40.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The recommendations described herein are a result of expert panel meetings, funded by Eusapharma. Eusapharma was not involved in neither the interpretation of the discussions and recommendations, nor in the preparation of the manuscript, but provided honoraria for medical writing support.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to S. Vázquez Estévez.

Ethics declarations

Conflict of interest

Dr. Martín Lázaro has been consultant for BMS, MSD, Takeda, Roche, Pfizer, Ipsen, Astra-Zeneca, Boehringer, Pierre-Fabre, Bayer. Has been speaker for Roche, Ipsen, Lilly, Astellas, Janssen, Novartis, Boehringer, Vifor. Has received grant or travel support from MSD, Ipsen, Roche, Janssen, Pfizer, Astellas, Pierre-Fabre. Dr. Anido Herranz reports non-financial support and other from Pfizer, personal fees, non-financial support and other from Novartis, non-financial support and other from Bayer, personal fees, non-financial support and other from Ipsen, other from EUSA, non-financial support and other from Sanofi, non-financial support and other from Advanced Accelerator Applications, grants and non-financial support from Pierre Fabre, personal fees and non-financial support from BMS, non-financial support from Roche, personal fees and non-financial support from Astellas, personal fees from Janssen, personal fees from Kyowa Kirin, personal fees from Lilly, outside the submitted work. Dr. Vázquez Estévez reports non-financial support and other from Pfizer, personal fees, non-financial support and other from Novartis, non-financial support and other from Bayer, personal fees, non-financial support and other from Ipsen, other from EUSA, non-financial support and other from Sanofi, grants and non-financial support from Pierre Fabre, personal fees and non-financial support from BMS, non-financial support from Roche, personal fees and non-financial support from Astellas, personal fees from Janssen. Dr. Fernández has had consultant or advisore role for Astellas Pharma, Roche, Pfizer, Bristol-Myers-Squibb, Sanofi, EUSA Pharma and Sanofi; has received honorari as speaker for Pierre-Fabre, Novartis, Bristol-Myers-Squibb, Ipsen, Roche, Astellas Pharma, Bayer and Janssen; has received travel/accommodations fees from Bristol-Myers-Squibb, Ipsen, Astellas. Rest of the authors have no relevant conflicts of interests.

Research involving human participants and/or animals

The manuscript does not contain clinical studies or patient data.

Informed consent

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vázquez Estévez, S., Anido, U., Lázaro, M. et al. A new scenario in metastatic renal cell carcinoma: a SOG-GU consensus. Clin Transl Oncol 22, 1565–1579 (2020). https://doi.org/10.1007/s12094-020-02300-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-020-02300-2

Keywords

Navigation